Aberg, Judith A <br/><br/>
Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.  [electronic resource] 

 -  AIDS research and human retroviruses  Oct 2012 
 - 1184-95 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1931-8405 
<br/><br/><label>Standard No.: </label>10.1089/aid.2011.0327  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acquired Immunodeficiency Syndrome--drug therapy<br/>Adult<br/>Aged<br/>Atazanavir Sulfate<br/>Biomarkers--blood<br/>CD4 Lymphocyte Count<br/>Darunavir<br/>Disease Progression<br/>Drug Administration Schedule<br/>Drug Resistance, Viral<br/>Drug Therapy, Combination<br/>Female<br/>Glomerular Filtration Rate<br/>HIV Protease Inhibitors--administration & dosage<br/>HIV-1--drug effects<br/>Humans<br/>Insulin Resistance<br/>Lipids--blood<br/>Male<br/>Middle Aged<br/>Oligopeptides--administration & dosage<br/>Pilot Projects<br/>Pyridines--administration & dosage<br/>RNA, Viral--blood<br/>Ritonavir--administration & dosage<br/>Sulfonamides--administration & dosage<br/>Time Factors<br/>Treatment Outcome<br/>Viral Load<br/>Young Adult